iRhythm Puts $100 Million Of Its $200 Million Buyback Plan Into Motion

The heart-monitoring company expects to use existing cash and finish settling the accelerated repurchase by the first quarter of 2027.

Share
iRhythm Puts $100 Million Of Its $200 Million Buyback Plan Into Motion

iRhythm Holdings, which helps doctors diagnose irregular heart rhythms through wearable monitoring, agreed Tuesday to a $100 million accelerated buyback. The company said in its SEC filing that the agreement implements part of a repurchase program authorizing up to $200 million, disclosed last Thursday.

Cash Committed, Buying Power Left

JPMorgan Chase Bank will handle the accelerated repurchase. iRhythm will pay the bank $100 million upfront and expects to draw that money from cash and cash equivalents already on hand.

The company expects approximately $100 million to remain available under its authorization once the accelerated transaction is completed. The signed agreement therefore advances the broader program without using all of its authorized spending.

IRTC shares rose about 2% to $97.10 in Thursday trading.

An Upfront Delivery, A Variable Count

iRhythm will initially receive shares covering approximately 80% of the number it expects to buy through the agreement. The final quantity depends on trading prices during the repurchase period.

The pricing formula uses daily average prices weighted by trading volume on specified trading days, then applies a discount and contractual adjustments. The $100 million commitment sets the spending amount; the agreement's pricing formula determines how many shares that buys.

At settlement, JPMorgan may deliver additional shares. In certain circumstances, iRhythm may instead owe the bank cash, or choose to deliver shares.

The Business Behind The Buyback

iRhythm's Zio system combines a wireless wearable patch with cloud software to record and analyze the heart's electrical signals. The patch can collect recordings for up to 14 days, helping physicians identify arrhythmias.

Technicians at the company's Medicare-enrolled testing facilities review reports before sending them to prescribing doctors. Physician practices and health systems are its customers, including cardiology and primary care practices.

The business operates mainly in the United States and has a commercial presence in the United Kingdom, selected European countries and Japan. Since its first FDA clearance, iRhythm has delivered more than twelve million patient reports.

iRhythm expects final settlement no later than the first quarter of 2027. JPMorgan has the option to accelerate settlement, and the agreement can end early in certain circumstances.

Sources

More on iRhythm Holdings

All iRhythm Holdings (IRTC) coverage →